Oral News and Research

RSS

Vitamin C may reduce cancer-linked digestive chemical reactions

A new study from the University of Waterloo uses mathematical modeling to examine how Vitamin C affects chemical reactions in the digestive system that are linked to cancer development.

20 May 2026

Ensitrelvir cuts household COVID-19 risk when given after exposure

Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.0% of placebo recipients, with similar overall adverse-event rates.

20 May 2026

Gut-localized drug avoids systemic safety risks while reversing hormonal imbalances in mice

Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women of reproductive age. It can cause irregular periods, infertility, weight gain, insulin resistance, and elevated male hormone levels. Current treatments mainly focus on managing symptoms rather than addressing underlying causes.

20 May 2026

Switching to pod-based e-cigarette could improve the odds of quitting smoking

Cigarette smoking is the leading preventable cause of death in the United States, even as rates of cigarette smoking have fallen to an all-time low of approximately 10% in 2024.

19 May 2026

Once-nightly oral pill helps control obstructive sleep apnea

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference.

18 May 2026

Gut microbiome metabolite butyrate relieves chronic jaw joint pain

Temporomandibular joint (TMJ) pain is associated with disrupted gut microbiome metabolites. Researchers reveal that butyrate, administered as tributyrin, alleviates pain by restoring histone acetylation and reversing gene regulatory changes in the brain.

18 May 2026

Multi-institutional trial explores new lifeline for advanced prostate patients

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close.

15 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

Study identifies breakthrough drug combination for early-stage Peyronie’s

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Adult weight gain strongly linked to higher obesity-related cancer risk

New research presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity related cancers.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

PET/CT scans reveal biological activity of aggressive head and neck tumors

A research team led by the Medical University of Vienna has demonstrated in a recent study that the biological characteristics of a subgroup of head and neck tumors - which are very aggressive in many cases - are reflected in modern imaging techniques.

13 May 2026

Cannabis and tobacco co-use may increase psychosis risk

A new multisite study published in Nature Mental Health found that using cannabis and tobacco together increases the risk of developing psychotic disorders like schizophrenia among those considered high risk.

12 May 2026

AI-powered handheld microscope may improve early cancer detection

Researchers at Rice University and The University of Texas MD Anderson Cancer Center have developed a compact, artificial intelligence-powered imaging device that could transform how clinicians detect cancer.

12 May 2026

Molecular switch in mice links energy burning and bone health

Scientists' discovery of a molecular "switch" that activates an energy‑burning pathway in mice has the potential to lead to new treatments for bone disease.

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Exercise or caffeine? Study finds neither clearly beats placebo for mental fatigue

Researchers compare the effects of caffeine and aerobic exercise on mental fatigue in adults.

10 May 2026

Slow and steady wins: Low-dose peanut immunotherapy safely desensitizes 82% of preschoolers in landmark trial

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

10 May 2026